/
Oncology
Solid Tumors
137
Pipeline Programs↗
114
Active Trials↗
125
Companies Involved↗
Solid Tumors is a highly competitive landscape with 137 programs across 125 companies. The most active players are Suzhou Suncadia Biopharmaceuticals Co., Ltd., Revolution Medicines, Guangzhou Gloria Biosciences Co., Ltd.. 8 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical6
Phase 166
Phase 257
Phase 38
Approved
No programs
Analysis
Modality Breakdown
79%
Small molecule
99 of 125 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 125 classified programs, each share of the total. Modality classified for 100% of 137 pipeline programs.
Analysis
Trial Status
460
clinical trials
Completed214 · 47%
Terminated75 · 16%
Recruiting69 · 15%
Unknown status33 · 7%
Active, not recruiting31 · 7%
Withdrawn16 · 3%
Other22 · 5%
Clinical Trials
Trial Activity
460 trials
PD-L1 Specific 68Ga-THP-PD-L1-3 Probe for PET Imaging in Solid Tumors
Recruiting·—·N/A·NCT06383598·50 enrolled
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
Recruiting·IInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.·Phase 1·NCT06963281·285 enrolled
Anti-cancer DC Cell Vaccination to Treat Solid Tumors
Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 1·NCT06477614·60 enrolled
NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors
Recruiting·—·N/A·NCT06509490·9 enrolled
Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors
Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 1·NCT06195384·30 enrolled
Page 1 of 31
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)